Showing results (201-210 of 421) with videos related to

Sort By:
Pageof 43
The Prostate|July 29, 2014
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancerPawel Osmulski, Devalingam Mahalingam, Maria E Gaczynska, et al.
Frontiers in Oncology|January 31, 2022
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialZhihong Gong, Mary E Platek, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 6, 2009
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialElizabeth A Platz, Cathee Till, Phyllis J Goodman, et al.
Urology|February 22, 2011
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032David C Smith, Cathy M Tangen, Peter J Van Veldhuizen, et al.
Cancer Research|April 19, 2006
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridizationSapna Vijayakumar, Devon C Hall, Xavier T Reveles, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
Urologic Oncology|July 31, 2004
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncologyWilliam E Grizzle, O John Semmes, Joseph Basler, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.
The Journal of Urology|January 27, 2009
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialIan M Thompson, Catherine M Tangen, Jorge Paradelo, et al.
Pageof 43